1 mL BAC
50 units
resulting U-100 draw
- Concentration
- 10 mg/mL
- BAC added
- 1 mL
Shown in the diagram. Closest of these examples to 25 units.
SinglePreclinicalPreclinicalVery Low confidenceSourced
MOTS-C
A mitochondrial-derived peptide supported mainly by cell and animal experiments. Human research largely measures endogenous MOTS-C rather than administering it.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community-provenance subcutaneous line from an authenticated research forum - 5 mg three times weekly (MWF) during a mitochondria cycle, tapering to weekly. Community reports only, not a validated or trial-verified schedule.
Reported maximum quantity
MWF then weekly taper (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.Reported cycle phases
Select a point for its calculation examples- 3x weekly (MWF)5 mgRun after roughly four weeks of daily SS-31 prep; reported quantities range from 2.5 mg every other day up to 10 mg twice weekly.
- Weekly taper5 mgTaper to 1x/weekSame 5 mg quantity, reduced to once weekly; the full cycle is repeated roughly twice a year.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 5 mg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
1 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw50 U
20-30 U reference band
2 mL BAC
100 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 2 mL
3 mL BAC
150 units
resulting U-100 draw
- Concentration
- 3.333 mg/mL
- BAC added
- 3 mL
This draw exceeds a 1 mL U-100 syringe.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 5 mg research vial
0.5 mg daily in weeks 1-2, 1 mg in weeks 3-4, 1.5 mg in weeks 5-6 and 2 mg in weeks 7-8
Human publications mainly measure endogenous MOTS-C; they do not validate this exogenous administration schedule. The source describes community research practice.
View sourceCommunity GuideSubcutaneous in reportsDivided weekly use; cycle varies
online research community summary and mitochondrial stacks
The spotlight states 5-10 mg subcutaneously per week in divided administrations; common stack examples use 5 mg three times weekly for four weeks, then 10 mg weekly
The channel expressly says there is no standard human native-MOTS-C protocol. Schedules range from low daily use to 15 mg three times weekly, and the only human administration trial discussed used a modified analogue; raw/peptide-education/pe-mots-c.md:19-21 and 238-284.
View sourceCommunity GuideSubcutaneous in reports3x weekly (MWF) then weekly; cyclical
authenticated research-forum (Peppys) reports and a mitochondria-stack protocol
Subcutaneous reports cluster around 5 mg three times weekly (Monday/Wednesday/Friday) during the MOTS-C phase of an SS-31 to MOTS-C to NAD+ cycle, tapering to 5 mg once weekly and repeated roughly twice a year; reported quantities conflict from 2.5 mg every other day up to 10 mg twice weekly
Forum provenance from an authenticated archive with usernames omitted. The archive stresses there are zero human administration studies and that the figures are extrapolated from animal data; reports also note the solution is acidic and stings unless pH-adjusted. Reported quantities conflict and are community provenance, not controlled human dose finding.
View sourceEvidence summary
A mitochondrial-derived peptide supported mainly by cell and animal experiments. Human research largely measures endogenous MOTS-C rather than administering it.
Protocol basis
The evidence page separates human observational physiology from exogenous animal dosing. Neither supplies a defensible injected human protocol.
Community provenance (Peppys)
An authenticated research-forum archive treats MOTS-C as the middle step of a mitochondria cycle, with subcutaneous reports clustering around 5 mg three times weekly after an SS-31 prep phase, then tapering to weekly and repeated roughly twice a year. Reported quantities conflict, spanning 2.5 mg every other day up to 10 mg twice weekly, and members flag that the solution reads acidic and stings unless pH-adjusted, with suspected precipitation weeks after reconstitution. The archive stresses there are no human administration studies, so every figure is extrapolated from animal data. Usernames are omitted and quantities are logged as community provenance; the planner above reproduces their arithmetic without validating them.
What remains uncertain
Human pharmacokinetics, dose-response, safety, formulation and clinically meaningful outcomes remain unestablished.
Warnings and contraindications
No validated human administration schedule for exogenous MOTS-C was identified.
Animal quantities do not convert directly into a human protocol.
Metabolic and exercise claims remain experimental.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.